A checklist, not a narrative
AI drug discovery stocks are easy to get excited about and hard to value, because the pitch is always a narrative and the risk is always in the details. The “sub-$10 AI drug stock” promotion from Alexander Green’s Oxford Club is a good example. The story, an AI platform that becomes a royalty business, is compelling. The question that matters is whether the numbers and the timeline support it, and that question is answered with a checklist, not a headline.
The example company behind the tease is Absci, an AI-powered drug discovery firm, and it makes a useful case study because it sits right in the middle of the risk spectrum: real partners, a clinical-stage asset, and a valuation that has already moved well past the “undiscovered” framing the ad still uses.
Check the cash runway first
Early-stage biotech lives or dies on cash. A company with a great platform and no runway gets diluted into irrelevance, because running clinical trials is expensive and the money has to come from somewhere. The useful question is not whether the company has cash today, but how far that cash carries it before the next raise.
Absci has been reinforced on this front. The AMD collaboration came with a $20 million investment in January 2025, and Eli Lilly put in $40 million tied to the lead program. Those strategic investments are a form of validation, and they buy runway. But they do not change the basic math: a clinical-stage company will likely raise again before it reaches revenue, and each raise dilutes existing holders.
Follow the milestone payments
For a partnership-driven company, the revenue is milestone payments, and the pattern of those payments tells you how the platform is actually performing. Absci’s deals, Merck worth up to about $610 million and AstraZeneca worth up to about $247 million, are structured around development progress. The “up to” matters: the full number only arrives if the program advances through every stage.
That is why the revenue line looks lumpy. A big milestone can land in one quarter and nothing in the next, and the promo’s “185% growth this year” and “300% more in 2027” figures are possible precisely because the base is small and the payments are uneven. For a deeper look at how that revenue model works, see our best royalty stocks explainer.
Price the platform against the pipeline
The cleanest way to size an AI drug discovery stock is to separate what the market is paying for the platform from what it is paying for the pipeline. Absci’s lead asset, ABS-201, is an antibody for pattern hair loss with proof-of-concept data expected in the second half of 2026. A useful yardstick is Veradermics, which is in late Phase 3 with an oral hair-loss treatment and carries a market cap around $5 billion on that single asset.
That comparison frames the bull case and the bear case at once. If one late-stage hair-loss drug can support $5 billion, Absci at roughly $1.69 billion is arguably being valued mostly for its platform, with the drug as an option on top. The risk is that the option expires: if the proof-of-concept data disappoints, the platform valuation has to stand on its own, and platform valuations are exactly the thing that got ahead of themselves in the last AI cycle. We map the leading companies in our AI drug discovery companies guide.
The three questions that matter most
Strip away the narrative and three questions decide whether an AI drug discovery stock is worth buying. First, does the company have a drug candidate in clinical trials, or just a platform and a partnership? Second, is the cash runway long enough to reach the next catalyst without a dilutive raise? Third, does the current valuation already price in the best case, as opposed to leaving room for it?
Absci is a reasonable place to run that checklist. It has a clinical asset, a reinforced balance sheet, and a valuation that has already climbed well above the “sub-$10 microcap” story the ad still tells. That does not make it a bad investment; it makes it a stock where the work is in the numbers, not the narrative.
None of this is a one-time exercise. The runway, the milestones, and the valuation all shift with every quarter and every readout, and the checklist is meant to be re-run against new data. A company that passed the test a year ago can fail it today, and the reverse is equally true.
Ready to see the research? Click here to access Alexander Green’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.